* ImaRx Pharmaceutical Corp., of Tucson, Ariz., said Phase I trialsof its vascular ultrasound contrast agent, MRX-115 Aerosomes,demonstrated positive results in measuring blood flow through theheart muscle to detect heart disease. Phase II trials are expected tobegin later this year.
* InFerGene Co., of Fort Smith, Ark., which filed forreorganizational bankruptcy protection in 1991, has agreed to mergewith Zaxis Inc., of Hudson, Ohio, a company that markets productsfor gel electrophoresis. The combined companies will be called ZaxisInternational Inc.
* U.S. Bioscience Inc., of West Conshohocken, Pa., has launchedsales of Ethyol, a selective cytoprotective agent, in Germany. TheEuropean Union's Committee for Proprietary Medicinal Productsrecommended approval for the drug in September 1994 for reductionof neutropenia-related infection in advanced ovarian cancer patients.Ethyol also has been cleared for marketing in France, Spain,Luxembourg and the U.K.
* Cambridge Neuroscience Inc., of Cambridge, Mass., started aplacebo-controlled study of Cerestat in stroke patients, who will betreated with fixed rather than weight-adjusted doses of the drug.
* Genetronics Biomedical Ltd., of San Diego, signed a contract tosupport gene therapy studies being conducted at The TorontoHospital. One area being studied is the feasibility of electroporationas a means to enhance gene transfer, using nonviral vectors.
* Immunomedics Inc., of Morris Plains, N.J., said a district courtgranted its motion to dismiss a shareholder lawsuit filed June 2, 1994.The complaint alleged the company gave misleading statementsabout its prospects.
* PerSeptive Biosystems Inc. said it completed its relocation to newheadquarters in Framingham, Mass. The company secured a $5million financing from Hambrecht & Quist Guaranty Finance L.P. tohelp offset the move.
* Repligen Corp., of Cambridge, Mass., and researchers from theUniversity of North Carolina at Chapel Hill reported that thecompany's recombinant platelet factor 4 (rPF4) appears to beeffective at restoring coagulation by reversing the effects of heparin,suggesting it may be an alternative to protamine for restoration ofcoagulation in cardiovascular patients.
* Shareholders of Anergen Inc., of Redwood City, Calif., approvedthe previously announced $15 million financing.
* The U.S. District Court for the Northern District of Californiagranted a motion from Alza Corp., of Palo Alto, Calif., to dismiss alawsuit brought against Alza by Cygnus Therapeutic Systems, ofRedwood City, Calif. Cygnus was challenging Alza's patent coverageof fentanyl transdermal patches.
* Viral Technologies Inc., of Alexandria, Va., a joint venture ownedby CEL-SCI Corp. and Alpha 1 Biomedicals Inc., started a clinicalstudy of HGP-30, an AIDS vaccine candidate. It will involve HIV-negative people who participated in a previous study.
(c) 1997 American Health Consultants. All rights reserved.